Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01420679 · MORE INFO

Limitations, agreements, and source contact

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients · Source last updated 2021-11-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
The study was prematurely terminated due to business reasons. There were no safety concerns that led to study closure. No efficacy assessments and analysis was conducted. A full statistical analysis and report were not completed.
point Of Contact
email
gajanan.Bhat@sppirx.com
organization
Spectrum Pharmaceuticals, Inc
phone
949-743-9219
title
Gajanan Bhat
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
The study was prematurely terminated due to business reasons. There were no safety concerns that led to study closure. No efficacy assessments and analysis was conducted. A full statistical analysis and report were not completed.
point Of Contact
email
gajanan.Bhat@sppirx.com
organization
Spectrum Pharmaceuticals, Inc
phone
949-743-9219
title
Gajanan Bhat

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice